RxDoctor Payments Data

Tara Atta, MD

Cardiovascular Disease · Vernon Hills, ILNPI 1639166374

Payments from drug & device makers

$4,416in general payments, 2019–2025

Across 178 payments — averaging $24.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Johnson & Johnson$626
  • Novo Nordisk$530
  • Boehringer Ingelheim$372
  • E.r. Squibb & Sons, L.L.C.$334
  • Amgen$244
  • plus $841 from 11 others

What the payments were for

  • Food & beverage$4,416100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,416 in reported general payments places this provider in the 65th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$120,335
Medicare patients
1,106
Services billed
2,339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban221$246,537
XareltoRivaroxaban76$92,004
Repatha SureclickEvolocumab42$34,054
EntrestoSacubitril/Valsartan21$27,396
Repatha PushtronexEvolocumab17$10,295
JardianceEmpagliflozin13$7,924
Praluent PenAlirocumab14$6,796
Ezetimibe195$4,108
Rosuvastatin Calcium252$4,068
Metoprolol Succinate251$3,865
Atorvastatin Calcium385$2,687
Amlodipine Besylate206$1,547
Amiodarone Hcl31$1,310
Carvedilol143$1,283
ClopidogrelClopidogrel Bisulfate102$1,255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$56$246,537221 claims
Johnson & JohnsonXarelto$626$92,00476 claims
NovartisEntresto$1,469$27,39621 claims
Boehringer IngelheimJardiance$372$7,92413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Vernon Hills

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →